Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918468 | 0.90 | HTR2C (0.34) | HTR2CHTR6 | |
| Hydrochloric Acid SCHEMBL27851765 | 0.88 | HTR2C (0.33) | HTR2CHTR6 | |
| SCHEMBL19343110 | 0.86 | HTR6 (0.37) | HTR2CHTR6ALDH1A1L3MBTL1L3MBTL3 | |
| SCHEMBL10053933 | 0.86 | HTR2C (0.45) | HTR2CHTR6RAD52ALDH1A1L3MBTL1 | |
| SCHEMBL11968900 | 0.86 | GNAI3 (0.36) | HTR2CHTR6L3MBTL3 | |
| SCHEMBL12356939 | 0.84 | HTR2C (0.46) | HTR2CHTR6RAD52ALDH1A1L3MBTL1 | |
| SCHEMBL10260365 | 0.84 | HTR2C (0.35) | HTR2CHTR6RAD52L3MBTL3 | |
| SCHEMBL20384029 | 0.84 | L3MBTL3 (0.40) | HTR2CL3MBTL3 | |
| SCHEMBL2227674 | 0.81 | CHRNB2 (0.32) | HTR2C | |
| SCHEMBL24672102 | 0.79 | GNAI3 (0.37) | RAD52L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440446-B | Benzothiazine-4-ketone compound containing oximino fragment and preparation method thereof | 中国医学科学院医药生物技术研究所 | 2020-05-15 | — | — | CN | disclosed |
| CN-107899539-A | There is magnetic montmorillonite being modified based on sodium of adsorption function and preparation method thereof to caesium | 北京源清益壤环保科技有限公司 | 2018-04-13 | — | — | CN | disclosed |
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| CN-1950351-B | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | WARNER LAMBERT CO | 2012-01-18 | — | — | CN | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| CN-1950351-A | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | TLR5, TLR2, PIR | HTR2C 2654/4885HTR6 3667/4885RAD52 4415/4885 |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | NISCH, PAK6, MYD88 | HTR2C 4196/4885HTR6 728/4885RAD52 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.